The government is complicit in the failure of community pharmacies by allowing these reimbursement practices to continue, especially under Medicare.

The big three pharmacy benefit managers will not disclose their pricing structures, making it impossible for clients to know if they are being charged fairly.

The big pharmacy benefit managers prioritize profits over everything, operating in an opaque industry where they can manipulate prices without accountability.

Insurance companies and pharmacy benefit managers (PBMs) often dictate which medications are authorized, sometimes requiring patients to try cheaper alternatives first, regardless of their effectiveness.

Pharmacy benefit managers often prevent access to cheaper biosimilars like YUSIMRY because they do not receive rebates on them, prioritizing profit over patient savings.

Cost Plus Drugs is working with independent pharmacies to create supportive programs that can help break the current cartel-like structure of the pharmaceutical industry.

Healthcare's inefficiencies stem from a complex mix of factors, including local monopolies and misaligned incentives that do not prioritize patient outcomes.

Big pharma is a business that often prioritizes keeping drugs out of generic status to maintain high prices, which can hinder the discovery of new drugs.

When dealing with big pharmacy benefit managers, obtaining claims data can be a lengthy and frustrating process, often requiring significant pressure to receive any information.